Prior to leading In Vivo, Lucie was a senior editor at Scrip and Pink Sheet. She is responsible for the production of In Vivo online as well as the annual Outlook publication. Covering the biopharma space since 2012, Lucie writes feature articles on the topics of leadership, R&D, innovation and more. She also regularly attends industry events and moderates panel discussions on topics such as investment trends, women’s health and R&D hot topics.
Latest from Lucie Ellis-Taitt
The biopharmaceutical landscape in 2026 will be shaped by rapid technological progress, shifting geographic leadership, a looming patent cliff and a renewed focus on capital efficiency.
Entering 2026, Lupin is positioning itself for growth, with a keen focus on the expanding ophthalmology market.
“Tubulis is not a single-asset company… It’s an innovation powerhouse,” said CEO Dominik Schumacher in an interview with In Vivo. He outlined the company’s clinical progress, funding momentum and how Tubulis will navigate the competitive biotech market in 2026.
In this special In Vivo podcast episode, executive editor Lucie Ellis-Taitt is joined by an expert panel of Citeline journalists – Ashley Yeo, David Wild, Jessica Merrill and data journalist Edwin Elmhirst – to explore the trends set to reshape the biopharma and medtech sectors as we head into 2026.
Abivax reflects on a transformative year marked by landmark clinical success and ambitious plans for the future.
There will be no return to normal for the European biopharma sector which needs to turn increasing macro-pressures into opportunities and become leaner and more efficient, experts at BIO-Europe said this week.